Skip to main content
. 2019 Mar 16;20(6):1334. doi: 10.3390/ijms20061334

Figure 3.

Figure 3

(A) Association of DNA methylation level (low and high) with disease-free survival. The survival curve demonstrates a shorter disease-free survival time in patients with lower methylation level of the evaluated CpG in PFKFB2 promoter. (B) BRAF mutation (V600E) and TERT promoter mutation (C228T and C250T) in relation to disease-free survival. These alterations were not related to the relapse risk in the studied cohort. BRAF mutation evaluation (pyrosequencing) was performed only for papillary thyroid carcinomas (PTC) samples, and TERT promoter mutation assay (Sanger sequencing) was performed for all well-differentiated thyroid carcinomas (WDTC). (C) Disease-free survival according to the recurrence risk categories considering the clinical-pathological features (American Thyroid Association recurrence risk stratification method) [4]. Low methylation levels: below the median; high methylation levels: above the median; WT: wild type.